10 Best Small-Cap Growth Stocks to Buy Now

2. UroGen Pharma Ltd. (NASDAQ:URGN)

3-Year Sales Growth: 30.91%

Number of Hedge Fund Holders: 30

UroGen Pharma Ltd. (NASDAQ:URGN) focuses on developing innovative treatments for urothelial and specialty cancers, as well as urologic diseases. The company uses a proprietary technology called RTGel, which is a reverse-thermal hydrogel that helps drugs stay in the body longer, making them more effective. Its main products include Jelmyto (MitoGel or UGN-101) and VesiGel (UGN-102). These treatments aim to ablate tumors without surgery, offering patients more effective and less invasive options for managing their conditions.

The company is making significant progress with UGN-102, a groundbreaking therapy for low-grade intermediate-risk non-muscle invasive bladder cancer. The FDA has accepted a New Drug Application for UGN-102, with a Prescription Drug User Fee Act target date of June 13, 2025. This is a pivotal step toward potential approval, which could make UGN-102 the first FDA-approved treatment for LG-IR-NMIBC. The market for UGN-102 is substantial, with over 80,000 addressable patients annually in the US, representing a potential market size of over $5 billion.

On February 19, Ladenburg kept a Buy rating on the stock with a price target of $31. The firm noted that they see a smooth path for the approval of  UGN-102, which will be a positive step for UroGen Pharma Ltd. (NASDAQ:URGN). It is one of the best small-cap growth stocks to buy now.